Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Les Laboratoires Servier, 50, rue Carnot, 92284 Suresnes cedex, France
Coversyl Arginine 2.5 mg film-coated tablets.
Coversyl Arginine 5 mg film-coated tablets.
Coversyl Arginine 10 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. 2.5mg: White, round, convex, film-coated tablet. 5mg: Light-green, rod-shaped film-coated tablet engraved with 10mg: Green, round, biconvex, film-coated tablet engraved with a ♡ on one face and |
Perindopril arginine.
2.5mg: One film-coated tablet contains 1.6975 mg perindopril corresponding to 2.5 mg perindopril arginine.
Excipient with known effect: 36.29 mg lactose monohydrate.
5mg: One film-coated tablet contains 3.395 mg perindopril corresponding to 5 mg perindopril arginine.
Excipient with known effect: 72.58 mg lactose monohydrate.
10mg: One film-coated tablet contains 6.790 mg perindopril corresponding to 10 mg perindopril arginine.
Excipient with known effect: 145.16 mg lactose monohydrate.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Perindopril |
Perindopril is an inhibitor of the enzyme that converts angiotensin I into angiotensin II (Angiotensin Converting Enzyme ACE). The converting enzyme, or kinase, is an exopeptidase that allows conversion of angiotensin I into the vasoconstrictor angiotensin II as well as causing the degradation of the vasodilator bradykinin into an inactive heptapeptide. Inhibition of ACE results in a reduction of angiotensin II in the plasma, which leads to increased plasma renin activity (by inhibition of the negative feedback of renin release) and reduced secretion of aldosterone. Since ACE inactivates bradykinin, inhibition of ACE also results in an increased activity of circulating and local kallikrein-kinin systems (and thus also activation of the prostaglandin system). |
| List of Excipients |
|---|
|
Core: Lactose monohydrate Film-coating: Glycerol |
White polypropylene tablet container equipped with a polyethylene flow reducer and a white opaque stopper containing a desiccant gel.
Box of 5, 10, 14, 20, 28, 30, 50, 60 (60 or 2 containers of 30), 84 (84 or 3 containers of 28), 90 (90 or 3 containers of 30), 100 (100 or 2 containers of 50), 120 (120 or 4 containers of 30) or 500 tablets (500 or 10 containers of 50).
Not all pack sizes may be marketed.
Les Laboratoires Servier, 50, rue Carnot, 92284 Suresnes cedex, France
2.5mg: PL 05815/0035
5mg: PL 05815/0036
10mg: PL 05815/0037
28/02/2007 – 10/12/2009
| Drug | Countries | |
|---|---|---|
| COVERSYL | Australia, Brazil, Cyprus, Ecuador, Spain, Finland, France, Ireland, Italy, Japan, Malta, Mexico, Nigeria, Netherlands, New Zealand, Singapore, Tunisia, Turkey, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
on one face and scored on both edges. The tablet can be divided into equal doses.